New approaches for anticoagulation in extracorporeal therapy

Area of Science:

• Biomedical Engineering
• Pharmacology
• Hematology

Background:

• Extracorporeal therapies often require full heparinization, increasing risks of hemorrhagic complications.
• Existing low molecular weight heparins are polydisperse and may not offer optimal specificity.

Purpose of the Study:

• To investigate strategies for mitigating hemorrhagic complications associated with extracorporeal therapy.
• To evaluate the efficacy of heparin elimination systems and novel very low molecular weight (VLMW) heparins.

Main Methods:

• Utilizing an immobilized heparinase reactor to eliminate heparin from blood after extracorporeal circulation.
• Developing and characterizing pure, monodisperse, structurally defined VLMW heparins.
• Assessing the pharmacokinetic and pharmacodynamic properties of new VLMW heparins.

Main Results:

• Animal studies confirmed successful heparin elimination and reversal of anticoagulant activity using the heparinase reactor.
• New VLMW heparins demonstrated improved pharmacokinetics and greater specificity compared to traditional heparin.
• Potential for partial anticoagulation with VLMW heparins, balancing antithrombotic and hemorrhagic effects.

Conclusions:

• Both heparinase reactor systems and novel VLMW heparins show promise in reducing bleeding risks during extracorporeal therapy.
• VLMW heparins offer a more defined and potentially safer alternative to current anticoagulation strategies.
• Structural insights from VLMW heparins may guide the development of blood-compatible synthetic materials for medical devices.